Table 2.
Clinical characteristics of patients with PIK3CA mutation (n = 23)
| Case | Gender/age | Stage | Concurrent genes | EGFR‐TKI | Everolimus | PFS of EGFR‐TKI | PFS of everolimus | OS |
|---|---|---|---|---|---|---|---|---|
| 1 | M/69 | IA | EGFR | – | – | – | – | 62.3M |
| 2 | M/43 | IIIA | KRAS | – | – | – | – | 53.7M |
| 3 | F/51 | IIIA | EGFR | Icotinib | – | 7.0M | 44.3M | |
| 4 | M/74 | IB | EGFR | – | 41.1M | |||
| 5 | F/60 | IA | ALK | – | – | – | – | 33.1M+ |
| 6 | M/64 | IB | KRAS | – | 48.9M+ | |||
| 7 | M/45 | IIIA | – | Gefitinib | Yes | 1.5M | 3.0M | 12.5M |
| 8 | M/62 | IIA | EGFR | Icotinib | – | 11.0M | 24.7M+ | |
| 9 | F/75 | IIIA | KRAS | – | – | – | – | 21M |
| 10 | F/69 | IB | EGFR | – | – | 19M+ | ||
| 11 | M/69 | IIB | EGFR | – | – | – | – | 32.2M |
| 12 | M/61 | IIIA | EGFR | Icotinib | – | 4.0M | 12.0M | |
| 13 | M/55 | IIIA | ALK | – | 21M | |||
| 14 | F/68 | IB | – | Icotinib | Yes | 2.5M | 4.0M | 26M |
| 15 | M/64 | IB | – | – | 16.8M+ | |||
| 16 | M/63 | IB | – | – | – | – | – | 16M+ |
| 17 | M/61 | IIB | EGFR | Gefitinib | Yes | 5.5M | 1.5M | 17.8M |
| 18 | F/31 | IIIA | EGFR | Gefitinib | – | 8.5M | 21M | |
| 19 | F/43 | IIIA | EGFR | Erlotinib | – | – | – | 17M |
| 20 | M/59 | IIIA | – | – | 1.2M | 17M | ||
| 21 | F/61 | IIIA | – | – | – | 16M+ | ||
| 22 | F/44 | IIA | EGFR | Icotinib | Yes (continue icotinib) | 9.5M | 6.0M | 32M |
| 23 | M/58 | IB | EGFR | – | 24M+ |
M: male; F: female; PFS: progression‐free survival; M: month; OS: overall survival.